Harary arrives at a critical juncture for the New York-based startup, which seeks to standardize a new drug category combining conventional prescriptions with personalized behavioral and cognitive software. His two-decade career includes senior leadership roles at Teva, where he directed R&D in neuroscience and immunology, contributing to the development of therapies like UZEDY and AUSTEDO. He also brings extensive experience in implementing machine learning and big data strategies within drug development lifecycles.
In section Releases
Remepy Recruits Teva Veteran Eran Harary to Lead Hybrid Drug Pipeline
As Remepy prepares to launch Phase III clinical trials for its Parkinson’s disease treatment, the company has appointed former Teva Pharmaceuticals executive Eran Harary as Chief Medical Officer. Harary will oversee the firm's strategy for integrating traditional pharmacology with AI-driven digital therapeutics starting October 1.
Co-CEOs Michal Tsur and Or Shoval noted that Harary’s expertise in both early and late-stage development aligns with the company’s goal to transition its Hybridopa program into global Phase III testing by the fourth quarter of 2026. For his part, Harary emphasized the potential of non-pharmaceutical interventions to amplify molecular therapeutic effects. He intends to leverage the current regulatory climate to scale Remepy’s model, which aims to turn standard medications into adaptive, software-enabled treatment platforms.
Comments (0)
No comments yet. Be the first!